Following the advent of the triptans, the use of dihydroergotamine (DHE) declined, because of the ease of use and improved side effect profiles of triptans. However, there remain many patients who ...

Medically reviewed by Nicholas R. Metrus, MDMedically reviewed by Nicholas R. Metrus, MD Migraine prevention injection is one ...

Ischemic bowel disease. Severe hepatic impairment. Within 24 hours of ergot-type drugs (eg, methysergide, dihydroergotamine), or other 5-HT1 agonists. During or within 2 weeks after discontinuing ...

Ergots come in different formulations, including ergotamine and dihydroergotamine. People use ergotamine to treat long-lasting migraine attacks that typically involve headache recurrence.

PULM) has dosed first subject in its Phase 1 trial evaluating PUR3100 for the treatment of acute migraine. PUR3100 is an orally-inhaled Dihydroergotamine (DHE) acute migraine therapy.

Dihydroergotamine in an orally inhaled form has completed Phase III trials. The novel delivery system consists of an inhaler (TEMPO®; MAP Pharmaceuticals), which uses a breath-triggered ...